Prime Medicine
PRME
About: Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.
Employees: 214
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
21% more capital invested
Capital invested by funds: $120M [Q1] → $145M (+$24.7M) [Q2]
17% more call options, than puts
Call options by funds: $1.42M | Put options by funds: $1.22M
9% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 34
0% more funds holding in top 10
Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]
9% less first-time investments, than exits
New positions opened: 29 | Existing positions closed: 32
1.31% less ownership
Funds ownership: 46.02% [Q1] → 44.71% (-1.31%) [Q2]
2% less funds holding
Funds holding: 123 [Q1] → 120 (-3) [Q2]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
|
Chardan Capital
Geulah Livshits
|
$10
|
Buy
Maintained
|
8 Aug 2025 |
Financial journalist opinion
Based on 3 articles about PRME published over the past 30 days
